Well Referenced

Tag: Hormonal therapy

A Prospective Audit of Intermittent Anti-Androgen versus Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate Cancer

This prospective audit compares the effects of intermittent anti-androgen therapy and pituitary blockade in patients with untreated prostate cancer. The results suggest that a bipolar androgen therapy strategy, which alternates between high and low levels of androgens, may offer a safe and effective treatment approach. The study highlights the potential

Read More »
June 26, 2025 No Comments

The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia

This randomized controlled trial investigated the effects of finasteride on scalp and serum dihydrotestosterone (DHT) levels in men with androgenetic alopecia. Involving 249 male participants over 42 days, the study demonstrated that finasteride, a 5α-reductase type 2 inhibitor, significantly reduced both scalp and serum DHT in a dose-dependent manner—scalp DHT

Read More »
June 26, 2025 No Comments

Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old

This randomized controlled trial, published in the British Journal of Dermatology (2008, PMID: 18363752), evaluated the hormonal impact and treatment response of daily 1 mg finasteride in 270 males aged 14–58 with androgenetic alopecia (AGA), using the Hamilton-Norwood scale III–VI. Over 12 months, younger participants (≤26 years) with higher baseline

Read More »
June 26, 2025 No Comments

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

This systematic review and meta-analysis evaluated the efficacy and safety of non-steroidal antiandrogen (NSAA) monotherapy compared to luteinising hormone-releasing hormone (LHRH) agonists or surgical castration in advanced prostate cancer. The study found that NSAA monotherapy was associated with a higher risk of death (HR 1.25, 95% CI 1.05-1.48), increased clinical

Read More »
June 26, 2025 No Comments

Replacement of DHEA in aging men and women. Potential remedial effects

This study, published in the Annals of the New York Academy of Sciences in 1995 (PMID: 8597453), investigates the effects of dehydroepiandrosterone (DHEA) supplementation in aging men and women. DHEA was associated with increased anabolic growth factors, improved muscle strength and lean body mass, activated immune function, and enhanced quality

Read More »
June 26, 2025 No Comments

Clinical evaluation and management strategy for sexual dysfunction in men and women

This systematic review provides comprehensive guidelines for the evaluation and management of sexual dysfunction in both men and women, emphasizing a patient-centered and evidence-based approach. It highlights the importance of thorough clinical assessments, considering medical, psychological, and relational factors, and proposes tailored treatment strategies, including pharmacological options like phosphodiesterase type

Read More »
June 26, 2025 No Comments

DHEA enhances effects of weight training on muscle mass and strength in elderly women and men

The article titled “Dehydroepiandrosterone supplementation combined with weight training improves muscle mass and strength in elderly individuals” (American Journal of Physiology-Endocrinology and Metabolism, 2006, PMID: 16787962) is a randomized controlled trial evaluating the effects of DHEA supplementation combined with resistance training on muscle mass and strength in elderly adults. The

Read More »
June 26, 2025 No Comments

Menopause and stroke and the effects of hormonal therapy

This review discusses the impact of menopausal hormone therapy (HT) on stroke risk, particularly in postmenopausal women. It highlights that HT, especially with conjugated equine estrogen/medroxyprogesterone acetate (CEE/MPA) or CEE alone, increases the risk of ischemic stroke, particularly in women over 60. However, recent studies suggest that lower doses of

Read More »
June 26, 2025 No Comments

Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis examined the safety and serum estradiol levels associated with hormonal treatments for vulvovaginal atrophy (VVA) in breast cancer survivors. The findings indicate that certain hormonal therapies lead to minimal increases in serum estradiol levels, remaining within safe thresholds, and effectively alleviating VVA symptoms such as

Read More »
June 26, 2025 No Comments

How sex hormones promote skeletal muscle regeneration

The review article “How sex hormones promote skeletal muscle regeneration” explores the role of androgens and estrogens in skeletal muscle repair, highlighting how aging-related declines in these hormones reduce muscle regeneration efficiency. While androgens are well-known for their anabolic effects, recent findings indicate that estrogens also enhance muscle regeneration by

Read More »
June 26, 2025 No Comments